Evidence map›Paper›PMID 25470278›Full record

ArticleMolecules (Basel, Switzerland)2014

Radiosensitizing effect of schinifoline from Zanthoxylum schinifolium Sieb et Zucc on human non-small cell lung cancer A549 cells: a preliminary in vitro investigation.

Cheng-Fang Wang, Li Fan, Mei Tian, Xue-Song Qi, Jian-Xiang Liu, Jiang-Bin Feng, Shu-Shan Du, Xu Su, Yong-Yan Wang

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. On the Inhibitability of Natural Products Isolated fromMolecules (Basel, Switzerland) · 2021
    Article
  7. 2-Alkylquinolone alkaloid biosynthesis in the medicinal plantThe Journal of biological chemistry · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Cheng-Fang WangChina CDC Key Laboratory of Radiological Protection and Nuclear Emergency, National Institute for Radiological Protection, Chinese Center for Disease Control and Prevention, Beijing 100088, China. wangchengfang@mail.bnu.edu.cn.
Li FanChina CDC Key Laboratory of Radiological Protection and Nuclear Emergency, National Institute for Radiological Protection, Chinese Center for Disease Control and Prevention, Beijing 100088, China. msfl@sina.com.
Mei TianChina CDC Key Laboratory of Radiological Protection and Nuclear Emergency, National Institute for Radiological Protection, Chinese Center for Disease Control and Prevention, Beijing 100088, China. tianmei@nirp.cn.
Xue-Song QiChina CDC Key Laboratory of Radiological Protection and Nuclear Emergency, National Institute for Radiological Protection, Chinese Center for Disease Control and Prevention, Beijing 100088, China. cedar121@sina.com.
Jian-Xiang LiuChina CDC Key Laboratory of Radiological Protection and Nuclear Emergency, National Institute for Radiological Protection, Chinese Center for Disease Control and Prevention, Beijing 100088, China. jxlamy@gmail.com.
Jiang-Bin FengChina CDC Key Laboratory of Radiological Protection and Nuclear Emergency, National Institute for Radiological Protection, Chinese Center for Disease Control and Prevention, Beijing 100088, China. fengjiangbin@126.com.
Shu-Shan DuState Key Laboratory of Earth Surface Processes and Resource Ecology, Beijing Normal University, Beijing 100875, China. dushushan@bnu.edu.cn.
Xu SuChina CDC Key Laboratory of Radiological Protection and Nuclear Emergency, National Institute for Radiological Protection, Chinese Center for Disease Control and Prevention, Beijing 100088, China. suxu@nirp.cn.
Yong-Yan WangState Key Laboratory of Earth Surface Processes and Resource Ecology, Beijing Normal University, Beijing 100875, China. narcissus09@126.com.
Chinese Center For Disease Control and Prevention · CNBeijing Normal University · CNNational Institute for Radiological Protection · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Schinifoline (SF), a 4-quinolinone derivative, was found in Zanthoxylum schinifolium for the first time. 4-Quinolinone moieties are thought to have cytotoxic activity and are often used as a tubulin polymerization inhibitors, heterogeneous enzyme inhibitors and antiplatelet agents. However, very little information respect to radiosensitization has focused on SF. This work aimed to investigate the radiosensitizing effect of SF on A549 cells. The cell viability results indicated cytotoxicity of SF on A549 cells, with IC50 values of 33.7 ± 2.4, 21.9 ± 1.9 and 16.8 ± 2.2 μg/mL, respectively, after 6, 12, 24 h treatment with different concentrations, and the 10% or 20% IC50 concentration during 12 h was applied in later experiments. The results of cell proliferative inhibition and clonogenic assay showed that SF enhanced the radiosensitivity of A549 cells when applied before 60Co γ-irradiation and this effect was mainly time and concentration dependent. The flow cytometric data indicated that SF treatment before the irradiation increased the G2/M phase, thus improving the radiosensitivity of A549, leading to cell apoptosis. This paper is the first study that describes the in vitro radiosensitising, cell cycle and apoptotic-inducing effects of schinifoline.

Indexed as

ApoptosisCarcinoma, Non-Small-Cell LungCell Cycle CheckpointsCell Line, TumorCell ProliferationGamma RaysHumansLung NeoplasmsQuinolonesRadiation, IonizingRadiation-Sensitizing AgentsSesquiterpenesTumor Stem Cell AssayZanthoxylumbeta-elemeneQuinolonesRadiation-Sensitizing AgentsschinifolineSesquiterpenes

Identifiers

PMID25470278
PMCPMC6271024
OpenAlexW1990857141

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.